16 April 2021>: Original Paper
Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial
Arman Faravardeh 1DE* , Sanjeev Akkina 2DE , Rafael Villicana 3DE , Giselle Guerra 4DE , Misbah A. Moten 5ADE , Ulf Meier-Kriesche 5ADE , Daniel R. Stevens 5ACDE , Samir J. Patel 5DE , Suphamai Bunnapradist 6DEDOI: 10.12659/AOT.929535
Ann Transplant 2021; 26:e929535
Table 3 Fisher’s exact test was performed to compare the proportion of patients who either did or did not experience the adverse event.
Event, n (%) | Switched to LCPT | Remained on IR-Tac |
---|---|---|
N=26 | N=29 | |
Urinary tract infection | 1 (4) | 2 (7) |
Diarrhea | 1 (4) | 1 (3) |
Blood creatinine increased | 1 (4) | 1 (3) |
Anemia | 1 (4) | 0 |
Drug level increased | 1 (4) | 0 |
Dyspepsia | 1 (4) | 0 |
Hyperkalemia | 1 (4) | 0 |
Leukopenia | 1 (4) | 0 |
Nausea | 1 (4) | 0 |
Nephropathy toxic | 1 (4) | 0 |
Oral candidiasis | 0 | 1 (3) |
Renal function test abnormal | 1 (4) | 0 |
Urosepsis | 0 | 1 (3) |
Vomiting | 1 (4) | 0 |
IR-Tac – immediate-release tacrolimus; LCPT – LCP-tacrolimus. |